Clearly, pioglitazone must be taken orally in order to perform its diabetic disease control action.
Pioglitazone can be administered either as the sole active substance, as monotherapy, or in combination therapy with other antidiabetic drugs. It is therefore not surprising that there are pioglitazone medicines on the market combined with other active substances, such as metformin, alogliptin or glimepiride.
Most pioglitazone-containing medicines are available for sale to the public on repeatable prescription (RR). Since these medicines are classified as Tier A drugs, their cost can be reimbursed by the National Health System (NHS). Sometimes, however, the patient may need to pay for a ticket.
Medicines based on pioglitazone and alogliptin, on the other hand, in order to be dispensed, require the presentation of a restrictive repeatable prescription or RRL (drugs that can be sold to the public only on prescription from hospitals or specialists). However, even in this case, these are medicines classified as class A drugs for reimbursement purposes.
